Table 2.

Enhanced efficacy of saracatinib with 5-FU or cisplatin in gastric cancer cell lines

IC50, ╬╝mol/LCI (ED50)
Cell line5-FUCisplatin5-FUCisplatin
SNU2163.284.583.8440.838
NCI-N872.641.180.1420.197
SNU1>105.741.3481.458
SNU5>102.960.1190.914
SNU165.868.860.1931.562
SNU6014.621.540.5222.586
SNU620>10>100.7840.597
SNU638>104.991.7454.609
SNU668>10>102.91.048
SNU719>10>100.0350.007

NOTE: The IC50 values of 5-FU and cisplatin determined using an MTT assay are shown along with the CI for the combinations of saracatinib with 5-FU or cisplatin at the 50% fraction affected in 10 gastric cancer cell lines (CI > 1, antagonistic effect; CI = 1, additive effect; CI <1, synergistic effect).